32 Biosciences, a gastrointestinal (GI)-focused biotechnology company pioneering gut mucosal-immune science to prevent and treat GI diseases, today announced that it will officially launch its $40 ...
Florida Cancer Specialists & Research Institute, LLC (FCS) advances gastrointestinal cancer treatment through participation ...
Abaya, a Pamana ng Pilipino awardee in 2024, was recognized for her exemplary achievements and groundbreaking contributions ...
Factors like the microclimate of the Mediterranean and Black Sea and harvesting techniques followed, make Bursa black figs ...
New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx ...
Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first ...
A single-institution US study in the Journal of Allergy and Clinical Immunology: Global has reported a steady rise in ...
Health systems have been leaning into ASC development in recent years as patient preferences, value-based incentives and operational costs make the outpatient shift a central aspect of growth ...
If approved, DTX401 will be the first therapy approved to treat the underlying cause of GSDIaNOVATO, Calif., Dec. 30, 2025 ...
EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with ...
STMicroelectronics (STMicro) held its annual Techday event in Taipei on December 12, showcasing solutions across a wide range of applications. The event focused on four main themes: smart mobility, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback